ArticleCancer letters2009
Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.
Article in Cancer letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Innovative Metal-Organic Frameworks for Targeted Oral Cancer Therapy: A Review.Materials (Basel, Switzerland) · 2023Review
- Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growthOncology letters · 2014Article
- Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.Oral oncology · 2014Review
- Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia.Journal of biomedical research · 2014Article
- Antioxidant function of isoflavone and 3,3'-diindolylmethane: are they important for cancer prevention and therapy?Antioxidants & redox signaling · 2013Review
- Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.Carcinogenesis · 2013Article
- Molecular basis of 'hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling.Radiation oncology (London, England) · 2013Article
- The complexities of epidemiology and prevention of gastrointestinal cancers.International journal of molecular sciences · 2012Review
- Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.Carcinogenesis · 2012Article
- Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Molecular biology reports · 2012Article
- Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.International journal of biological sciences · 2012Article
- RETRACTED: Mechanisms and therapeutic implications of cell death induction by indole compounds.Cancers · 2011Article
- Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.International journal of cancer · 2011Article
- PAR-4 as a possible new target for pancreatic cancer therapy.Expert opinion on therapeutic targets · 2010Review
- Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.Mutation researchReview
Corrections and comments
- Retraction · 2018-03-29Falsification/Fabrication of Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author ·
- Retracted
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Cisplatin resistance is a major problem in the successful treatment of squamous cell carcinoma (SCC). In the present study we showed, for the first time, that the constitutive activation of NF-kappaB partly contributes to cisplatin resistance and that the inactivation of NF-kappaB by natural agents [G2535 (isoflavone mixture containing genistein and diadzein), 3,3'-diindolylmethane (Bioresponse BR-DIM referred to as B-DIM)] could overcome this resistance, resulting in the inhibition of cell growth and induction of apoptosis, which might be an useful strategy for achieving better treatment outcome in patients diagnosed with cisplatin-resistant tumors of SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.